Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: A case report

Journal of Pediatric Hematology/Oncology

Volumn 20, Issue 6, 1998, Pages 545-547

  Bergstrom, Steven K ^a,b   Gillan, Eileen ^a   Quinn, John J ^a   Altman, Arnold J ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b Division of Pediatric Infectious Diseases   (United States)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid; Arsenic trioxide; PML RAR fusion transcript

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CHIMERIC PROTEIN; RETINOIC ACID;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ARTHRALGIA; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CASE REPORT; CLINICAL FEATURE; CLINICAL PROTOCOL; DISEASE COURSE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MECHANISM; DRY SKIN; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; PRIORITY JOURNAL; RECURRENT CANCER; TOOTH PAIN; TREATMENT OUTCOME;

EID: 0032459325     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199811000-00006     Document Type: Article

References (15)

1. Forkner CE, Scott TFM. Arsenic as a therapeutic agent in chronic myelogenous leukemia. JAMA 1931;97:3-5.
2. Abernathy CO, Chappell WR, Meek ME, et al. Is inorganic arsenic a "threshold" carcinogen? Fundam Appl Toxicol 1996;29:168-75.
3. Grignani FR, Ferrucci PF, Testa U, et al. The acute promyelocytic leukemia-specific PML/RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 1993;74:423-31.
4. Koken MHM, Puvion-Dutilleul F, Guillemin MC, et al. The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J 1994;13:1073-83.
5. Dyck JA, Maul GG, Miller WH, et al. A novel macromolecular structure is a target of the promyelocytic-retinoic acid receptor oncoprotein. Cell 1994;76:333-43.
6. Mu ZM, LE XF. Glassman AB, et al. The biologic function of PMI and its role in acute promyelocytic leukemia. Leukemia Lymphoma 1996;23:277-85.
7. Chang K-S, Fan Y-H, Andreeff M, et al. The PML gene encodes a phosphoprotein associated with the nuclear matrix. Blood 1995;85:3646-53.
8. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997;337: 1021-8.
9. Rigas JR, Francis PA, Muindi JR, et al. Constitutive variability in the pharmacokinetics of the natural retinoid, all-trans-retinoic acid, and its modulation by ketokonozole. J Natl Cancer Inst 1993;85:1921-6.
10. Muindi JF, Young CW. Lipid hydroperoxides greatly increase the rate of oxidative catabolism of all-trans-retinoic acid by human cell culture microsomes genetically enriched in specified cytochrome P-450 isoforms. Cancer Res 1992;53:1226-9.
11. Cornic M, Delva L, Guidez F, et al. Induction of retinoic acid-binding protein in normal and malignant human myeloid cells by retinoic acid in acute promyelocytic leukemia patients. Cancer Res 1992;52:3329-34.
12. Warrell RP. Retinoid resistance in acute promyelocytic leukemia: new mechanisms, strategies, and implications. Blood 1993;82: 1949-53.
13. 3) in the treatment of acute promyelocytic leukemia (APL): II. clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-60.
14. Zhu J, Koken MHM, Quignon F, et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 1997;94:3978-83.
15. 3 exerts dose dependent dual effects on APL cells. Blood 1997;89: 3345-53.